Cargando…
Atrial fibrillation in heart failure: what should we do?
Heart failure (HF) and atrial fibrillation (AF) are two conditions that are likely to dominate the next 50 years of cardiovascular (CV) care. Both are increasingly prevalent and associated with high morbidity, mortality, and healthcare cost. They are closely inter-related with similar risk factors a...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4670966/ https://www.ncbi.nlm.nih.gov/pubmed/26419625 http://dx.doi.org/10.1093/eurheartj/ehv513 |
_version_ | 1782404336151691264 |
---|---|
author | Kotecha, Dipak Piccini, Jonathan P. |
author_facet | Kotecha, Dipak Piccini, Jonathan P. |
author_sort | Kotecha, Dipak |
collection | PubMed |
description | Heart failure (HF) and atrial fibrillation (AF) are two conditions that are likely to dominate the next 50 years of cardiovascular (CV) care. Both are increasingly prevalent and associated with high morbidity, mortality, and healthcare cost. They are closely inter-related with similar risk factors and shared pathophysiology. Patients with concomitant HF and AF suffer from even worse symptoms and poorer prognosis, yet evidence-based evaluation and management of this group of patients is lacking. In this review, we evaluate the common mechanisms for the development of AF in HF patients and vice versa, focusing on the evidence for potential treatment strategies. Recent data have suggested that these patients may respond differently than those with HF or AF alone. These results highlight the clear clinical need to identify and treat according to best evidence, in order to prevent adverse outcomes and reduce the huge burden that HF and AF are expected to have on global healthcare systems in the future. We propose an easy-to-use clinical mnemonic to aid the initial management of newly discovered concomitant HF and AF, the CAN-TREAT HFrEF + AF algorithm (Cardioversion if compromised; Anticoagulation unless contraindication; Normalize fluid balance; Target initial heart rate <110 b.p.m.; Renin–angiotensin–aldosterone modification; Early consideration of rhythm control; Advanced HF therapies; Treatment of other CV disease). |
format | Online Article Text |
id | pubmed-4670966 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-46709662015-12-08 Atrial fibrillation in heart failure: what should we do? Kotecha, Dipak Piccini, Jonathan P. Eur Heart J Review Heart failure (HF) and atrial fibrillation (AF) are two conditions that are likely to dominate the next 50 years of cardiovascular (CV) care. Both are increasingly prevalent and associated with high morbidity, mortality, and healthcare cost. They are closely inter-related with similar risk factors and shared pathophysiology. Patients with concomitant HF and AF suffer from even worse symptoms and poorer prognosis, yet evidence-based evaluation and management of this group of patients is lacking. In this review, we evaluate the common mechanisms for the development of AF in HF patients and vice versa, focusing on the evidence for potential treatment strategies. Recent data have suggested that these patients may respond differently than those with HF or AF alone. These results highlight the clear clinical need to identify and treat according to best evidence, in order to prevent adverse outcomes and reduce the huge burden that HF and AF are expected to have on global healthcare systems in the future. We propose an easy-to-use clinical mnemonic to aid the initial management of newly discovered concomitant HF and AF, the CAN-TREAT HFrEF + AF algorithm (Cardioversion if compromised; Anticoagulation unless contraindication; Normalize fluid balance; Target initial heart rate <110 b.p.m.; Renin–angiotensin–aldosterone modification; Early consideration of rhythm control; Advanced HF therapies; Treatment of other CV disease). Oxford University Press 2015-12-07 2015-09-29 /pmc/articles/PMC4670966/ /pubmed/26419625 http://dx.doi.org/10.1093/eurheartj/ehv513 Text en © The Author 2015. Published by Oxford University Press on behalf of the European Society of Cardiology. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Review Kotecha, Dipak Piccini, Jonathan P. Atrial fibrillation in heart failure: what should we do? |
title | Atrial fibrillation in heart failure: what should we do? |
title_full | Atrial fibrillation in heart failure: what should we do? |
title_fullStr | Atrial fibrillation in heart failure: what should we do? |
title_full_unstemmed | Atrial fibrillation in heart failure: what should we do? |
title_short | Atrial fibrillation in heart failure: what should we do? |
title_sort | atrial fibrillation in heart failure: what should we do? |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4670966/ https://www.ncbi.nlm.nih.gov/pubmed/26419625 http://dx.doi.org/10.1093/eurheartj/ehv513 |
work_keys_str_mv | AT kotechadipak atrialfibrillationinheartfailurewhatshouldwedo AT piccinijonathanp atrialfibrillationinheartfailurewhatshouldwedo |